Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
While most patients do not experience mood changes, higher-risk groups include: History of depression, anxiety, or bipolar disorder ADHD or dopamine-sensitive conditions Very rapid weight loss Inadequate protein or electrolyte intake Poor sleep quality Lower risk is associated with: Slow dose titration Adequate nutrition Stable blood sugar Good sleep hygiene What Clinicians and Patients Can Do Before Starting a GLP-1 Screen for mood disorders Set expectations about appetite changes Discuss minimum nutrition goals During Treatment Monitor caloric intake (not just weight) Prioritize protein and hydration Watch for glucose variability Adjust dose slowly If Irritability Appears Assess nutrition first Evaluate sleep and reflux Consider dose adjustment Monitor mood over time In many cases, simple nutritional adjustments or slower titration resolve symptoms without stopping the medication
They are not substitutes for each other and address different aspects of body composition and metabolic health
Administration of AEA and a selective CB2R agonist, JWH-015, showed a significant improvement in inflammation, as evidenced by a reduction in mucosal crypt loss, luminal epithelial damage, and lymphocyte infiltration in the LP
Am I a Good Candidate for GLP-1 agonist
